Actualités et vidéos - FORTY SEVEN INC.

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML -- -- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket Pharmaceuticals to Expand Development Program -- -- Gilead Acquisition of Forty Seven Expected to Close in 2Q 2020 -- MENLO PARK, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate...

MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with Rocket’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy, RP-L102. The initial...

MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences: Cowen 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at 8:40 a.m. ET in Boston, MA. 32 nd Annual ROTH Conference on Monday, March 16, 2020 at 10:00 a.m. PT (1:00 p.m. ET) in Dana Point, CA....

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences: Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY. 9 th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 11:30 a.m....

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk MDS and AML Expected Mid-Year 2020 -- -- Initial Data from Phase 3 Trial in DLBCL Expected in 4Q 2020 -- -- FSI-174 and FSI-189 Expected to Enter Phase 1 in 1Q and 2Q 2020, Respectively -- -- FDA Granted Orphan Drug Designation for Magrolimab in MDS -- MENLO PARK, Calif., Jan....

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000 shares of common stock, including 729,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering, before underwriting discounts and commissions and offering expenses, were approximately $195.6...

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share. Gross proceeds to Forty Seven from the offering are expected to be $170.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common...

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a 30-day option to purchase up to $21,000,000 of additional shares of common stock. Morgan Stanley & Co....

-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 -- -- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced preclinical proof-of-concept data for its novel all antibody conditioning regimen, comprised of FSI-174,...

-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS -- -- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy -- -- Median Duration of Response Not Yet Reached, with Patients on Treatment for More than 6.4 and 8.8 Months for MDS and AML, Respectively -- -- Finalized Design of Clinical Program to Support Potential Accelerated Approval in Higher-Risk MDS -- -- Forty Seven to Host Investor Event and...

-- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 -- -- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin -- -- Management to Host Conference Call at 8:00 a.m. ET Today -- MENLO PARK, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against...

MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b study evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), including additional efficacy and durability data from a larger number of...

MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 8:00 a.m. ET (5:00 a.m. PT) on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update. The live call may be accessed by dialing (866) 953-0780 for domestic...

MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 8:20 a.m. ET in New York, NY. A live webcast of the fireside chat will be available...

MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 17 th Annual Global Healthcare Conference on Tuesday, September 10, 2019 at 2:55 p.m. ET in New York, NY. A live webcast of the fireside...

MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Magrolimab is a monoclonal antibody against CD47 that is designed to block...

-- Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings -- -- Received FDA Feedback Suggesting Single-Arm Pivotal Trials May Support Registration in MDS and DLBCL -- -- Entered Exclusive Licensing Agreement with Ono Pharmaceutical to Develop and Commercialize 5F9 in Japan, South Korea, Taiwan and the ASEAN Countries -- -- Raised $86.3 Million in Follow-On Offering, Extending Cash Runway Through First Quarter of 2021 -- -- Management to Host Conference Call at 4:30...

MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, August 13, 2019 to report its second quarter 2019 financial results and provide a corporate update. The live call may be accessed by dialing (866) 953-0780 for domestic...

MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced additional funding commitments from The Leukemia & Lymphoma Society (LLS), aimed at accelerating the development of 5F9 for the treatment of myelodysplastic syndromes (MDS). Forty Seven presented updated initial data from its Phase 1b clinical study of 5F9 in patients with MDS at the...

MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Canaccord Genuity 39 th Annual Growth Conference on Wednesday, August 7, 2019 at 3:30 p.m. ET in Boston, MA. A live webcast of the presentation will be...